detect
identif
drug
suscept
test
microbi
pathogen
repres
key
duti
microbi
diagnost
medicin
antibiot
suscept
test
especi
provid
import
inform
toward
adequ
treatment
decis
also
great
import
epidemiolog
genotyp
isol
microorgan
respect
monitor
surveil
rout
infect
essenti
task
order
develop
strategi
prevent
success
treat
infect
commun
health
care
facil
recent
progress
extens
research
microb
well
develop
new
nucleicacidbas
methodolog
result
increas
use
molecular
assay
clinic
laboratori
sever
commerci
test
avail
mainli
focu
review
nucleicacidbas
molecular
techniqu
identif
resist
determin
clinic
bacteriolog
give
brief
overview
current
use
modern
bacteri
diagnost
provid
outlook
futur
technolog
especi
deal
multiparametr
detect
infecti
diseaserel
determin
appropri
also
mention
exampl
field
clinic
microbiolog
eg
clinic
virolog
one
oldest
still
import
method
clinic
bacteriolog
detect
human
pathogen
direct
microscop
examin
specimen
mani
differ
stain
procedur
avail
gram
stain
giemsa
stain
stain
provid
first
rough
classif
detect
organ
howev
final
character
identif
still
reli
phenotyp
properti
organ
cultur
appropri
media
introduct
autom
laboratori
system
blood
cultur
system
bactec
becton
dickinson
franklin
lake
nj
usa
bactalert
marci
l
etoil
franc
increas
qualiti
effici
meet
high
requir
standard
also
identif
antimicrobi
drugsuscept
test
autom
system
vitek
phoenix
becton
dickinson
microscan
walkaway
siemen
healthcar
diagnost
munich
germani
well
establish
system
base
miniatur
convent
method
use
biochem
properti
identif
microdilut
suscept
test
howev
sophist
system
still
need
start
pure
cultur
sever
hour
identif
h
suscept
test
turnaround
time
specimen
therefor
still
requir
minim
h
usual
h
necessari
develop
immunoassay
allow
first
time
rapid
detect
identif
microorgan
without
cultur
assay
either
detect
presenc
specif
antibodi
rais
respons
pathogen
antigen
detect
antigen
techniqu
avail
variou
format
enzym
immunoassay
immunofluoresc
assay
latex
agglutin
assay
line
immunoassay
lateralflow
immunoassay
respect
direct
antigen
test
clinic
sampl
provid
rapid
specif
identif
result
howev
antigen
detect
still
suffer
lack
sensit
requir
compar
larg
amount
respect
antigen
case
screen
specif
antibodi
respons
human
immun
system
respect
pathogen
use
serodiagnosi
allow
differenti
acut
past
infect
although
continu
improv
past
serolog
ineffect
earli
diagnosi
infect
due
time
lag
seroconvers
except
molecular
test
nucleic
acid
amplif
techniqu
nat
direct
microscopi
specimen
cultur
direct
antigen
detect
repres
sole
possibl
detect
acut
infect
earli
possibl
face
either
lack
sensit
specif
long
time
period
result
avail
develop
realtim
pcr
assay
use
fluorescentlabel
probe
combin
amplif
technolog
pave
way
molecular
assay
clinic
microbiolog
mani
differ
realtim
pcr
instrument
detect
probe
format
avail
review
differ
probe
format
taqman
hydrolysi
probe
molecular
beacon
scorpion
probe
minor
groov
bind
probe
mani
detect
principl
explain
sinc
detail
inform
realtim
pcr
technolog
detect
format
frequent
provid
public
review
technolog
reli
principl
fluoresc
reson
energi
transfer
fret
fret
occur
two
fluorophor
close
proxim
energi
excit
donor
transfer
acceptor
fig
develop
closedtub
system
realtim
pcr
technolog
significantli
reduc
risk
contamin
strongli
contribut
strict
requir
clinic
diagnost
one
main
advantag
use
realtim
fluoresc
measur
abil
quantifi
genotyp
genet
variat
singlenucleotid
polymorph
snp
use
set
specif
probe
possibl
snp
nucleotid
within
assay
quantif
realtim
pcr
well
establish
virolog
eg
cytomegaloviru
cmv
monitor
hematooncolog
patient
neutropen
stage
stem
cell
transplant
human
immunodefici
viru
hiv
hepat
c
viru
hcv
also
determin
bacteri
load
establish
potenti
allow
monitor
antimicrobi
therapi
respons
discrimin
among
infect
colon
fig
cystic
fibrosi
cf
patient
suffer
chronic
lung
infect
lead
deterior
lung
function
import
pathogen
adult
cf
patient
pseudomona
aeruginosa
earli
diagnosi
p
aeruginosa
colon
stage
great
import
prompt
adequ
antibiot
treatment
aim
erad
pathogen
delay
onset
chronic
infect
pcrbase
screen
p
aeruginosa
colon
onset
gain
averag
month
convent
cultur
screen
also
sever
burn
patient
frequent
get
infect
p
aeruginosa
profit
earli
detect
quantif
p
aeruginosa
develop
quantit
pcr
detect
p
aeruginosa
wound
specimen
show
method
provid
result
within
h
concomit
minim
handsontim
allow
earli
antibiot
treatment
decis
made
correl
bacteri
load
sever
infect
also
shown
meningococc
diseas
exampl
show
first
realtim
pcr
assay
clinic
bacteriolog
still
stick
principl
monoparametr
analyt
one
assay
one
step
advanc
introduct
methicillinresist
staphylococcu
aureu
mrsa
realtim
pcr
assay
cepheid
xpert
mrsa
bd
geneohm
mrsa
first
time
speci
identif
name
aureu
resist
determin
name
methicillin
resist
detect
underli
meca
gene
cassett
sscmec
combin
singl
assay
possibl
upcom
assay
use
approach
might
detect
highli
virul
clostridium
difficil
ribotyp
directli
stool
specimen
recent
first
multiparametr
pcr
assay
diagnosi
bloodstream
infect
releas
identifi
differ
bacteri
fungal
pathogen
directli
whole
blood
septifast
roch
diagnost
mannheim
germani
vyoo
sirslab
jena
germani
sepsitest
blood
molzym
bremen
germani
bloodstream
infect
major
caus
morbid
mortal
worldwid
far
autom
blood
cultur
system
consid
gold
standard
detect
microbi
growth
base
detect
carbon
dioxid
product
despit
improv
growth
media
instrument
blood
cultur
slow
poor
diagnost
sensit
specif
left
hope
amplificationbas
method
direct
microbi
detect
whole
blood
potenti
increas
diagnost
sensit
specif
shorter
time
result
absolut
critic
point
adequ
treatment
sepsi
abovement
assay
use
principl
multiplex
pcr
mean
parallel
amplif
differ
target
one
tube
use
specif
primer
pair
determin
wherea
septifast
system
reli
realtim
pcr
lightcycl
technolog
use
fluoresc
melt
curv
analysi
vyoo
sepsitest
system
perform
convent
multiplex
pcr
subsequ
identif
specif
pcr
fragment
agaros
gel
electrophoresi
altern
hybrid
microarray
system
put
enorm
effort
develop
reliabl
sampl
prepar
crucial
assay
format
use
dnafre
reagent
equip
togeth
method
decreas
human
background
dna
looxster
sirslab
molysi
molzym
implement
diagnosi
bloodstream
infect
molecular
method
recent
review
klouch
et
al
last
decad
dna
sequenc
technolog
made
enorm
progress
regard
throughput
capabl
cost
per
reaction
userfriendli
dna
sequenc
becom
establish
routin
laboratori
autom
made
possibl
pcrbase
sequenc
reaction
capillari
electrophoresi
far
sequenc
use
identif
organ
difficult
identifi
use
convent
method
detect
identifi
uncultiv
organ
epidemiolog
phylogenet
point
view
ribosom
gene
target
choic
taxonomi
studi
repres
present
gold
standard
mani
ribosom
sequenc
avail
open
access
databas
use
produc
align
subsequ
speci
assign
current
sangerbas
sequenc
technolog
common
sequenc
method
nevertheless
technolog
pyrosequenc
singlecel
sequenc
current
describ
massiv
parallel
dna
sequenc
approach
promis
power
altern
futur
applic
clinic
microbiolog
abl
explain
fascin
technolog
review
would
like
pick
emuls
pcr
coupl
pyrosequenc
one
exampl
mani
differ
sequenc
techniqu
avail
fig
singlenucleotid
polymorph
analysi
repres
one
field
pyrosequenc
exhibit
excel
perform
base
enzymecascad
system
onlin
monitor
light
produc
result
incorpor
nucleotid
method
accur
userfriendli
larg
data
gener
short
time
stateoftheart
system
sequenc
million
nucleotid
h
rapid
result
advantag
diagnost
applic
timetoresult
essenti
sepsi
mening
howev
due
larg
amount
gener
data
power
interpret
softwar
requir
stress
need
equal
advanc
progress
bioinformat
begin
matrixassist
laser
desorptionion
timeofflight
mass
spectrometri
malditof
ms
appli
analysi
whole
bacteria
protein
sequenc
bacteri
nucleic
acid
use
malditof
ms
introduc
improv
basespecif
cleav
nucleic
acid
fragment
gener
differ
method
subsequ
analyz
result
mass
pattern
compar
refer
spectra
sequenc
speci
determin
respect
time
mass
spectrometri
microbi
genotyp
still
infanc
howev
larg
diagnost
center
alreadi
use
malditof
ms
bacteri
identif
fig
technolog
potenti
becom
method
choic
highthroughput
test
clinic
microbiolog
provid
accur
fast
automat
costeffici
result
respect
standard
solidphas
hybrid
use
specif
hybrid
probe
attach
solid
support
detect
label
target
molecul
solut
initi
assay
detect
identif
singl
paramet
specif
probe
immobil
well
microtit
plate
later
macroarray
fix
multipl
probe
specif
locat
nitrocellulos
nylon
membran
develop
differ
probe
appli
dot
dotblot
line
line
probe
assay
lipa
varieti
differ
lipa
assay
avail
eg
identif
mycobacterium
tuberculosi
complex
atyp
mycobacteria
combin
determin
common
genet
resist
determin
rifampin
isoniazid
also
lipa
determin
vancomycinresist
enterococci
vre
mrsa
c
difficil
toxin
ab
neisseria
meningitidi
enterohemorrhag
e
coli
ehec
extendedspectrum
betalactamas
esbl
metallobetalactamas
mbl
well
set
gramposit
neg
pathogen
posit
blood
cultur
market
dnastrip
hain
lifesci
nehren
germani
hyplex
test
bag
health
care
lich
germani
last
decad
develop
microarray
emerg
research
focus
mainli
gene
express
studi
compar
macroarray
microarray
miniatur
version
spot
size
usual
less
diamet
macroarray
usual
limit
fewer
probe
dna
microarray
vari
lowdens
array
carri
hundr
thousand
probe
highdens
array
contain
ten
thousand
million
spot
differ
label
detect
method
use
conjunct
arraybas
technolog
rang
fluoresc
silver
precipit
measur
enzymemedi
substrat
convers
use
microarray
diagnost
applic
microbiolog
still
begin
nevertheless
number
public
increas
therebi
variou
etiolog
agent
target
use
differ
approach
regard
target
molecul
surfac
chemistri
appli
peptideprotein
array
describ
detect
hivhcv
tuberculosi
antigen
microarray
diagnosi
blood
cultur
neg
endocard
respect
dna
microarray
appli
eg
diagnosi
bacteri
mening
show
accur
rapid
result
cerebrospin
fluid
csf
blood
cultur
result
well
acut
respiratori
tract
infect
children
caus
virus
field
even
without
pcr
amplif
first
commerci
avail
microarraybas
assay
suitabl
routin
applic
releas
market
like
papillocheck
hpv
screen
test
greiner
bioon
gmbh
frickenhausen
germani
microarraybas
papillocheck
hpv
screen
test
show
similar
result
compar
linear
array
hpv
genotyp
test
amplicor
hpv
test
roch
diagnost
howev
studi
show
eg
influenc
nucleic
acid
isol
method
use
therefor
need
standard
genotyp
method
great
potenti
applic
dna
microarray
lie
resist
genotyp
sinc
phenotyp
antimicrobi
resist
often
result
complex
network
differ
underli
genet
alter
requir
complex
parallel
detect
method
antimicrobi
resist
especi
threat
aris
multidrugresist
pathogen
one
import
urgent
problem
clinic
bacteriolog
usag
microarray
alreadi
demonstr
suitabl
gener
p
aeruginosa
one
import
pathogen
caus
nosocomi
infect
particular
nosocomi
pneumonia
show
high
capabl
develop
multidrug
resist
therebi
express
enorm
array
differ
underli
genet
resist
determin
describ
dna
microarray
genotyp
antibiot
resist
p
aeruginosa
target
variou
resist
mechan
multidrug
efflux
transport
porin
loss
target
alter
due
mutat
snp
small
insertionsdelet
resistancemedi
gene
present
plasmid
mobil
genet
element
respect
fig
assay
differ
resistancerel
dna
fragment
amplifi
parallel
encod
total
differ
genet
resist
determin
genotypephenotyp
correl
almost
addit
genotypebas
predict
rate
higher
initi
observ
phenotyp
correl
well
known
induct
phenomenon
phenotyp
express
resist
therapi
furthermor
complex
resist
problem
detect
hundr
differ
esbl
variant
tem
oxa
shv
ctxm
gene
mrsa
clinic
relev
resist
staphylococci
dna
microarray
assay
publish
assay
although
need
optim
regard
implement
routin
clinic
laboratori
character
compar
short
time
requir
h
compar
convent
method
besid
fact
resistancerel
inform
crucial
adequ
treatment
lifethreaten
infect
determin
assign
organ
genotyp
time
obtain
inform
use
concomit
epidemiolog
surveil
although
describ
p
aeruginosa
microarray
repres
statu
research
approach
current
process
partial
integr
complet
diagnost
devic
includ
sampl
prepar
multiplex
pcr
amplif
array
hybrid
result
readout
high
specif
high
sensit
short
time
requir
userfriendli
import
requir
microbi
diagnost
assay
use
threedimension
membran
structur
provid
increas
reaction
surfac
compar
flat
twodimension
surfac
allow
target
bind
enhanc
probetarget
interact
abil
measur
temperatur
variat
continu
monitor
reaction
use
fluoresc
technolog
allow
meltingcurv
analysi
instead
endpoint
detect
suspens
array
base
coupl
oligonucleotid
probe
microbead
colorcod
use
differ
ratio
two
fluoresc
dye
third
dye
use
gener
label
target
dna
subsequ
hybrid
suspens
set
differ
bead
carri
differ
probe
bead
mixtur
sort
flow
cytometri
base
intern
color
hybrid
sampl
produc
fluoresc
signal
fig
panel
detect
multipl
viral
strain
subtyp
use
technolog
approv
respiratori
diseas
diagnost
fda
xtag
respiratori
viral
panel
rvp
luminex
austin
texa
usa
other
diseas
like
meningococc
infect
current
develop
sepsi
diagnost
use
technolog
progress
recent
year
innov
microfluid
nanotechnolog
made
tremend
progress
make
technolog
cornerston
futur
clinic
diagnost
dna
protein
function
nanoparticl
fnp
exampl
spherelik
biocompat
materi
made
inert
silica
metal
crystal
nanomet
size
may
use
hybrid
probe
singlenucleotid
polymorph
snp
screen
detect
biolog
marker
cancer
infect
cardiovascular
diseas
precis
handl
small
amount
rang
nanolit
picolit
scale
microchannel
combin
sensit
detect
method
like
electrochem
microarray
predispos
technolog
pointofcar
poc
labonachip
loc
diagnost
allow
fabric
dispos
singleus
cartridg
result
rapid
afford
diagnost
without
need
sophist
expens
laboratori
equip
loc
microfluid
nanotechnolog
advantag
increas
sensit
mobil
effici
like
favor
uptak
privat
public
health
sector
innov
transit
digit
microfluid
rather
presentday
concept
continu
flow
microfluid
expect
attract
attent
diagnost
manufactur
determin
futur
technolog
loc
provid
short
timetoresult
inform
oppos
current
daylong
wait
make
vast
differ
diagnosi
treatment
mention
patient
outcom
present
loc
develop
test
sepsi
endocard
hiv
tuberculosi
sever
acut
respiratori
syndrom
sar
pneumonia
malaria
numer
infecti
diseas
alreadi
introduct
molecular
diagnost
technolog
human
genet
virolog
chang
way
clinic
diagnost
perform
field
number
diagnost
assay
clinic
bacteriolog
increas
steadili
last
decad
howev
convent
microbiolog
replac
immedi
futur
multiparamet
identif
import
pathogen
use
arraybas
detect
technolog
rapid
realtim
pcrbase
assay
becom
common
today
laboratori
advanc
autom
decreas
cost
molecular
microbiolog
bring
tool
closer
routin
laboratori
improv
multiplex
strategi
analysi
technolog
like
malditof
ms
might
harbor
potenti
cope
evid
problem
modern
medicin
especi
steadili
increas
threat
multidrugresist
pathogen
combin
rapidli
advanc
innov
microfluid
futur
trend
clearli
point
toward
complex
multiparametr
assay
miniatur
autom
labonachip
devic
also
suitabl
pointofcar
diagnost
